The lancet oncology
-
The lancet oncology · Jul 2022
Observational StudyImpact of the COVID-19 pandemic on the diagnosis of cancer in Japan: an observational study of hospital-based cancer registries data.
There is an important concern that the COVID-19 pandemic has negatively affected cancer care worldwide. We used a national database to assess the effect of the COVID-19 pandemic on the diagnosis of cancer in Japan. ⋯ This study was supported by the Health, Labour and Welfare Policy Research Grants, Research for Promotion of Cancer Control Programmes (reference 21EA2003), and the Cancer Research and Development Fund of the National Cancer Centre, Japan (reference 2020-A-20).
-
The lancet oncology · Jul 2022
Randomized Controlled TrialNivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib showed superior progression-free survival, overall survival, and objective response over sunitinib in patients with previously untreated advanced renal cell carcinoma (median follow-up of 18·1 months). Here, we report extended follow-up of overall survival and updated efficacy and safety. ⋯ Bristol Myers Squibb and Ono Pharmaceutical.
-
The lancet oncology · Jul 2022
Radiotherapy and cancer status in Latin America: economic analysis of investment opportunities up to 2030.
Timely access to radiotherapy treatments for cancer in Latin America is hindered by substantial delays in investment. We herein report on the current incidence of the ten most frequent malignancies and on radiotherapy-related logistics across Latin America with the objective of identifying resource gaps and facilitate the planning of health-care investments up to 2030. ⋯ None.
-
The lancet oncology · Jul 2022
Serious health-related suffering in Latin America: a secondary analysis.
Evidence from needs analysis can support health systems and improve morbidity and mortality rates related to life-limiting and life-threatening conditions, and is essential for the development of health care and educational plans to respond adequately to the disease burden of the population. The aim of this study was to establish the number of people with serious health-related suffering, defined as a negative impact on the functioning (eg, physical, social, or emotional) of a patient with a serious illness that cannot be mitigated without medical intervention, in 19 Spanish-speaking and Portuguese-speaking Latin American countries in 1990, 2000, 2010, and 2019. ⋯ None.